16 December 2015
Researchers: Dunja Przulj[1], Hayden McRobbie[1], Oliver Knight-West[2], Peter Hajek[1]
[1] Health and Lifestyles Research Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK.
[2] National Institute for Health Innovation, School of Population Health, University of Auckland, New Zealand.
Key findings
- Clients using varenicline were more likely to report reduced enjoyment of drinking compared to those using NRT at 4 weeks post target-quit-day.
- Varenicline did not reduce alcohol consumption, compared to NRT.
- Varenicline also had no effect on alcohol consumption or enjoyment in a sub-group of hazardous-harmful drinkers.
- There were no differences between Varenicline ‘reactors’ (clients who reported a 50% reduction in smoking in the first week of use) and non-reactors on consumption or enjoyment of alcohol.
